Evidence map›Paper›PMID 29511355›Full record

ArticleBreast cancer : basic and clinical research2018

Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab.

John Syrios, Evelina Pappa, Nikolaos Volakakis, Anastasios Grivas, John Alafis, Sofia Manioudaki, Vasiliki Tzouda, Athanasios Korogiannos, Cleopatra Rapti, Nektarios Koufopoulos and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer : basic and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

John SyriosOncology Department, Hygeia & Mitera Hospital, Marousi, Greece.
Evelina PappaFaculty of Social Sciences, Hellenic Open University, Patras, Greece.
Nikolaos Volakakis2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, Athens, Greece.
Anastasios GrivasDepartment of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece.
John Alafis2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, Athens, Greece.
Sofia Manioudaki2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, Athens, Greece.
Vasiliki TzoudaOncology Department, Hygeia & Mitera Hospital, Marousi, Greece.
Athanasios Korogiannos2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, Athens, Greece.
Cleopatra Rapti2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, Athens, Greece.
Nektarios KoufopoulosPathology Lab, "St. Savvas" Cancer Hospital, Athens, Greece.
Adamantia NikolaidouOncology Department, Hygeia & Mitera Hospital, Marousi, Greece.
Eleftheria KanavouUniversity Mental Health Research Institute, Athens, Greece.
Athanasios AlexopoulosOncology Department, Hygeia & Mitera Hospital, Marousi, Greece.
Anna KoumarianouHematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
St Savas Hospital · GRMitera Hospital · GRHellenic Open University · GRMetaxa Hospital · GRNational and Kapodistrian University of Athens · GRUniversity Mental Health Research Institute · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein. Recently, a newer subcutaneous formulation was shown to have comparable efficacy to the initial intravenous trastuzumab. In this study, we aimed to evaluate the impact of subcutaneous trastuzumab on the health-related quality of life (HRQoL) of patients diagnosed with early or metastatic HER2-overexpressing breast cancer.

methodsPatients were provided with the EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) and the BR-23 questionnaires. The scoring of questionnaires and patient's sociodemographic and clinicopathologic characteristics were recorded and analyzed by descriptive and correlation statistics employing

resultsA total of 163 patients agreed to participate in the study. About 90 of 163 patients (55.21%) received subcutaneous trastuzumab and 21 patients intravenous trastuzumab (12.88%). A control group of 52 HER2+ patients received chemotherapy without trastuzumab (31.90%). Patients receiving subcutaneous trastuzumab were older and of more advanced disease stage compared with those receiving chemotherapy (58.5 vs 51 years, 39.8% vs 28.8% advanced disease). In univariate analysis, subcutaneous trastuzumab was associated with less nausea and vomiting (

conclusionsThe administration of subcutaneous trastuzumab improved certain symptoms and did not adversely affect most of the assessed functional scales. Particularly, in the metastatic setting, subcutaneous trastuzumab had no negative impact on HRQoL.

Indexed as

Breast cancerchemotherapyhealth-related quality of lifeHER2 proteinQLQ-C30 and BR-23 questionnairesubcutaneous trastuzumab

Identifiers

PMID29511355
PMCPMC5826003
OpenAlexW2790214362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.